Sana Biotechnology Inc
SANA
Get informed when a big investor buys or sells
+ FollowMarket Cap$979.59M
Close$
$-0.03
100.8% downside
Current Fair Value
100.8% downsideOvervalued by 100.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $979.59 Million |
|---|---|
| Enterprise Value | $971.11 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.96 |
| Beta | 2.14 |
| Outstanding Shares | 276,856,000 |
Return
| Return on Equity | -202.94% |
|---|---|
| Return on Assets | -64.77% |
| Return on Invested Capital | -80.69% |
Valuation & Multiples
| P/E Ratio | -3.78 |
|---|---|
| PEG | 85.79 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.19 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.63 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 44.04% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 12.21%▼ 47.08% |
|---|---|
| Total Invested | $117.57M▼ 75.13% |
| Investors Holding | 74▼ 132.00% |
ESG Score
No data
About Sana Biotechnology Inc
265 employeesSana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. Sana shares a vision of repairing and controlling genes, replacing missing or damaged cells, and making its therapies broadly avai...